Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MPO | P05164 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29726475 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KDM4EGAAMPOKIF11 | |
| SCHEMBL15234505 | 0.84 | KIF11 (0.54) | KIF11EGLN2CA12CA2CA9 | |
| SCHEMBL29726483 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM4EGAAMPOKIF11 | |
| SCHEMBL165867 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM4EGAAMPOKIF11 | |
| Methane SCHEMBL27670217 | 0.80 | ALDH1A1 (0.48) | ALDH1A1KDM4EGAAMPOKIF11 | |
| Hydrochloric Acid SCHEMBL29261706 | 0.80 | ALDH1A1 (0.48) | ALDH1A1KDM4EGAAMPOKIF11 | |
| SCHEMBL20372969 | 0.79 | CTSD (0.48) | KDM4EGAACA2CA9 | |
| SCHEMBL1477509 | 0.79 | CYP11B1 (0.43) | — | |
| SCHEMBL352155 | 0.78 | ALDH1A1 (0.50) | ALDH1A1KDM4EGAAEGLN2LOXL2 | |
| SCHEMBL29443092 | 0.78 | ALDH1A1 (0.50) | ALDH1A1KDM4EGAAEGLN2LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-02-19 | — | — | US | disclosed |
| US-12448379-B2 | Wild type kit inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-06-05 | — | — | US | disclosed |
| CN-116655497-B | Amidine derivative compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2025-06-03 | — | — | CN | disclosed |
| US-20250092014-A1 | COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE | METREA BIOSCIENCES INC (US) | 2025-03-20 | — | — | US | disclosed |
| CN-118946553-A | SARM1 inhibitor compound, pharmaceutical composition comprising the same, and preparation method and use thereof | 深圳众格生物科技有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-114206870-B | Tricyclic AKR1C 3-dependent KARS inhibitors | 诺华股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-08-08 | — | — | US | disclosed |
| US-20240262826-A1 | WILD TYPE KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-08-08 | — | — | US | disclosed |
| CN-115232026-B | Cyano diamine-containing cyano functionalized polyimide mixed matrix membrane and preparation thereof | 东华大学 | 2024-07-30 | — | — | CN | disclosed |
| EP-2007774-A1 | THIAZOLYLDIHYDROINDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-12-31 | — | — | EP | disclosed |
| CN-101321525-A | Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors | HOFFMANN LA ROCHE (CH) | 2008-12-10 | — | — | CN | disclosed |
| EP-1959951-A1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | F. Hoffmann-la Roche AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20080081802-A1 | Thiazolyl-Dihydro-Indazole | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | disclosed |
| WO-2007113246-A1 | THIAZOLYLDIHYDROINDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | WO | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2007063012-A1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | US | disclosed |
| WO-2007035542-A1 | 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049080-A1 | WILD TYPE KIT INHIBITORS | KIT, CSNK1A1, CSNK1A1L | ALDH1A1 741/4885KDM4E 1183/4885GAA 1230/4885 |
| US-12448379-B2 | Wild type kit inhibitors | KIT, TNK1, TNNI3K | ALDH1A1 1830/4885KDM4E 1234/4885GAA 561/4885 |
| US-20080081802-A1 | Thiazolyl-Dihydro-Indazole | MKI67, CCNT1, CCNA1 | ALDH1A1 44/4885KDM4E 3312/4885GAA 998/4885 |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | ALDH1A1 234/4885KDM4E 1460/4885GAA 541/4885 |
| US-20250092014-A1 | COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE | LPL, LIPA, PNLIP | ALDH1A1 1201/4885KDM4E 4122/4885GAA 19/4885 |
| US-20240262826-A1 | WILD TYPE KIT INHIBITORS | KIT, TNK1, TNNI3K | ALDH1A1 1830/4885KDM4E 1234/4885GAA 561/4885 |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | ALDH1A1 234/4885KDM4E 1460/4885GAA 541/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | ALDH1A1 1806/4885KDM4E 2058/4885GAA 352/4885 |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | CPT1A, CPT1B, CPT2 | ALDH1A1 104/4885KDM4E 1133/4885GAA 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.